Antibodies specific to antigens of Bartonella henselae and use of these antigens in immunoassays

Abstract

Disclosed are antibodies that bind to the antigenic proteins GroES, RplL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the "BepA" protein) of Bartonella henselae, and use of these antigenic proteins in immunoassays in order to determine whether a sample from a subject contains one or more of these antibodies. Presence of such an antibody in the subject indicates that the subject is or was infected with Bartonella henselae, or indicates that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae. Also disclosed are kits for performing immunoassays, wherein each kit contains one or more of these antigenic proteins and also contains the reagents necessary for conducting an immunoassay.

Description

CROSS REFERENCES TO RELATED APPLICATIONS

[0001] The present application claims benefit, under 35 U.S.C. 119(e), to U.S. Provisional Application No. 60/684,707 entitled "Bartonella henselae antigens and use thereof in clinical serological assays," filed on May 26, 2005, the entire contents of which are hereby incorporated by reference.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention is broadly concerned with antibodies specific to antigens of Bartonella henselae and use of these antigens in immunoassays. More particularly, the present invention relates to antibodies specific to the GroES protein, the RplL protein, an expressed protein of unknown function (the "BepA" protein), the GroEL protein, the SodB protein, the UbiG protein, and the ABC transporter protein of Bartonella henselae, and use of these antigenic proteins in immunoassays in order to determine whether a patient is or was infected with Bartonella henselae.

[0004] 2. Description of the Related Art

[0005] Epidemiological, serological, and molecular studies have implicated Bartonella henselae as the primary causative agent of Cat Scratch Disease (CSD), a frequent self-limiting zoonotic condition which is transferred from cat scratches or bites to people (Bergmans, A. M., J. W. Groothedde, J. F. Schellekens, J. D. van Embden, J. M. Ossewaarde, and L. M. Schouls. 1995. Etiology of cat scratch disease: comparison of polymerase chain reaction detection of Bartonella (formerly Rochalimaea) and Afipia felis DNA with serology and skin tests. J. Infect. Dis. 171:916-23.). Development of CSD is common with a reported incidence rate of 0.77 to 0.86 cases per 100,000 people.

[0006] In the United States, approximately 22,000 people develop CSD annually (Koehler, J. E., C. A. Glaser, and J. W. Tappero. 1994. Rochalimaea henselae infection. A new zoonosis with the domestic cat as reservoir. JAMA 271:531-5; Peter, J. B., M. Boyle, M. Patnaik, T. L. Hadfield, N. E. Barka, W. A. Schwartzman, and R. S. Penny. 1994. Persistent generalized lymphadenopathy and non-Hodgkin's lymphoma in AIDS: association with Rochalimaea henselae infection. Clin. Diagn. Lab. Immunol. 1:115-6.). Approximately 11% of CSD cases are atypical and symptoms can include granulomatous conjunctivitis, oculoglandular syndrome, tonsillitis, visceral granulomatous disease, encephalitis, and cerebral arteritis (Schwartzman, W. A. 1992. Infections due to Rochalimaea: the expanding clinical spectrum. Clin. Infect. Dis. 15:893-900.).

[0007] Cats serve as a major reservoir of Bartonella henselae. Pathogen analyses of domesticated cats in the United States have estimated that approximately 28% are chronically infected with Bartonella henselae with no obvious clinical symptoms (Kordick, D. L., K. H. Wilson, D. J. Sexton, T. L. Hadfield, H. A. Berkhoff, and E. B. Breitschwerdt. 1995. Prolonged Bartonella bacteremia in cats associated with cat-scratch disease patients. J. Clin. Microbiol. 33:3245-51.).

[0008] Infection with Bartonella henselae in significant cases can result in bacillary angiomatitis or endocarditis. Children and immunocompromised individuals are especially vulnerable to this bacterium. In immunocompromised patients, including those who have been infected with HIV-1 and have developed AIDS, infection with Bartonella henselae can result in bacillary angiomatosis or peliosis hepatis and may also include visceral involvement (Fournier, P. E., and D. Raoult. 1998. Cat scratch disease and an overview of other Bartonella henselae related infections., p.32-62. In A. Schmidt (ed.), Bartonella and Afipia species emphasizing Bartonella henselae. Karger, Basel, Switzerland.). The U.S. Public Health Service and the Infectious Diseases Society of America has recognized the risk of contracting Bartonellosis, especially in immunocompromised HIV-1 infected individuals, and have published suggested guidelines for cat ownership as feline-to-human transmission of Bartonella henselae is the most commonly recognized route (Kaplan, J. E., H. Masur, and K. K. Holmes. 2002. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm. Rep. 51:1-52.).

[0009] Bartonella spp. also have been found in 39% of deer ticks (species: Ixodes scapularis) (Adelson, M. E., R. S. Rao, R. C. Tilton, K. Cabets, E. Eskow, L. Fein, J. C. Occi, and E. Mordechai. 2004. Prevalence of Borrelia burgdorferi, Bartonella spp., Babesia microti, and Anaplasma phagocytophila in Ixodes scapularis ticks collected in Northern New Jersey. J. Clin. Microbiol. 42:2799-801.). This information, in conjunction with a clinical case study in which patients were co-infected with Borrelia burgdorferi, the causative agent of Lyme Disease, and Bartonella henselae, suggests that tick bites may serve as an additional method of Bartonella henselae transmission (Eskow, E., R. V. Rao, and E. Mordechai. 2001. Concurrent infection of the central nervous system by Borrelia burgdorferi and Bartonella henselae: evidence for a novel tick-borne disease complex. Arch. Neurol. 58:1357-63.).

[0010] Current clinical diagnostics rely on culturing, immunofluorescence assay ("IFA"), and polymerase chain reaction ("PCR") technologies. The culturing of Bartonella from blood samples is technically challenging and is a low-yield procedure. Recommended growth conditions include lengthy incubation periods of at least twenty-one days on Columbia blood agar plates (Raoult, D., and R. Tilton. 1999. Dictionary of Infectious Diseases. Elsevier Publishing, New York.; Spach, D. H., and J. E. Koehler. 1998. Bartonella-associated infections. Infect. Dis. Clin. North. Am. 12:137-55.). Culturing of Bartonella is therefore not considered an effective and reproducible diagnostic procedure to detect Bartonella spp. infections.

[0011] Bartonella henselae IFAs have high sensitivity and specificity. However, cross-reactivity with other human pathogens, including Coxiella burnetii, Chlamydia spp., Rickettsia rickettsii, Ehrlichia chaffeensis, Treponema pallidum, Francisella tularensis, and Mycoplasma pneumoniae has been reported (Cooper, M. D., M. R. Hollingdale, J. W. Vinson, and J. Costa. 1976. A passive hemagglutination test for diagnosis of trench fever due to Rochalimaea quintana. J. Infect. Dis. 134:605-9.; Drancourt, M., J. L. Mainardi, P. Brouqui, F. Vandenesch, A. Carta, F. Lehnert, J. Etienne, F. Goldstein, J. Acar, and D. Raoult. 1995. Bartonella (Rochalimaea) quintana endocarditis in three homeless men. N. Engl. J. Med. 332:419-23.; McGill, S. L., R. L. Regnery, and K. L. Karem. 1998. Characterization of human immunoglobulin (Ig) isotype and IgG subclass response to Bartonella henselae infection. Infect. Immun. 66:5915-20.). In addition, IFAs rely heavily on technicians for the determination of test results which introduces subjectivity into the interpretation of these test results, are time-consuming to score, and require expensive fluorescent microscopes.

[0012] Bartonella PCR amplifies the 16S rRNA gene which permits the simultaneous detection of DNA from Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, Bartonella elizabethae, and Bartonella clarridgeiae (Bergmans, A. M., J. W. Groothedde, J. F. Schellekens, J. D. van Embden, J. M. Ossewaarde, and L. M. Schouls. 1995. Etiology of cat scratch disease: comparison of polymerase chain reaction detection of Bartonella (formerly Rochalimaea) and Afipia felis DNA with serology and skin tests. J. Infect. Dis. 171:916-23.). While allowing for species-specific identification, PCR requires the presence of Bartonella organisms or DNA in the tested sample.

[0013] The antibody response to Bartonella henselae has been studied in several different types of mammals; however, in order to develop sensitive and accurate serological assays, for example, the human antibody response to Bartonella henselae needs to be elucidated in detail. Identification of antigenic proteins, particularly, is of paramount importance to the creation of improved clinical diagnostics.

BRIEF SUMMARY OF THE INVENTION

[0014] The present invention provides the antigenic proteins noted in the preceding paragraph, wherein these proteins are useful, for example, in immunoassays capable of detecting antibodies specific to Bartonella henselae.

[0015] More specifically, the present invention is directed to an isolated antibody capable of binding to an antigen, wherein the antigen consists of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18. In an embodiment, the antibody is human. In another embodiment, the antibody is polyclonal.

[0016] The present invention also is drawn to a kit containing (a) an isolated antigen comprising the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18 and (b) the reagents necessary for conducting an immunoassay, wherein the immunoassay is capable of detecting the presence of an antibody in a sample, wherein the antibody is capable of binding to an antigen consisting of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18. In an embodiment, the immunoassay is an IFA. In another embodiment, the immunoassay is an enzyme-linked immunosorbent assay ("ELISA"). In yet another embodiment, the isolated antigen in (a) consists of the amino acid sequence of SEQ ID NO:I 1, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18.

[0017] The present invention also relates to a method for determining whether a subject contains an antibody capable of binding to an antigen consisting of the amino acid sequence of SEQ ID NO:I 1, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18 comprising (a) conducting an immunoassay on a sample from the subject, and (b) determining that the subject contains the antibody if the results of the immunoassay indicate that the antibody is present in the sample, or determining that the subject does not contain the antibody if the results of the immunoassay indicate that the antibody is not present in the sample. In an embodiment, the subject is human. In another embodiment, the immunoassay is an IFA. In yet another embodiment, the immunoassay is an ELISA.

[0018] The present invention also pertains to a method for determining whether a subject has an increased likelihood of being infected presently or in the past with Bartonella henselae comprising (a) conducting an immunoassay on a sample from the subject, and (b) determining that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae if the results of the immunoassay indicate that an antibody is present in the sample, or determining that the subject does not have an increased likelihood of being infected presently or in the past with Bartonella henselae if the results of the immunoassay indicate that the antibody is not present in the sample, wherein the antibody is capable of binding to an antigen consisting of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18. In an embodiment, the subject is human. In another embodiment, the immunoassay is an IFA. In yet another embodiment, the immunoassay is an ELISA.

[0019] The present invention also is drawn to a method for determining whether a subject has a present infection with Bartonella henselae or had a past infection with Bartonella henselae comprising (a) conducting an immunoassay on a sample from the subject, and (b) determining that the subject has a present infection with Bartonella henselae or had a past infection with Bartonella henselae if the results of the immunoassay indicate that an antibody is present in the sample, or determining that the subject does not have a present infection with Bartonella henselae or did not have a past infection with Bartonella henselae if the results of the immunoassay indicate that the antibody is not present in the sample, wherein the antibody is capable of binding to an antigen consisting of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18. In an embodiment, the subject is human. In another embodiment, the immunoassay is an IFA. In yet another embodiment, the immunoassay is an ELISA.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] FIG. 1 illustrates a two-dimensional analysis of proteins of Bartonella henselae. Soluble (A), less soluble (B), and insoluble (C) proteins derived from Bartonella henselae were separated based on isoelectric point (pI 5-8) and molecular weight. Gels were stained with Coomassie Blue. The soluble fractions were also separated using a larger pI range (3-10) (D) to visualize the majority of proteins found in Bartonella henselae.

[0021] FIG. 2 illustrates the reactivity of patient serum (A) and normal serum (B) to the soluble fraction of Bartonella henselae. Western blots shown are representative blots of fourteen patient sera and seven normal sera.

[0022] FIG. 3 illustrates the localization of Bartonella henselae proteins selected for further analysis. Coornassie-Blue stained two-dimensional SDS-PAGE gel with spots yielding greater than 63% reactivity to patient sera are circled and given an arbitrary letter designation for future reference.

[0023] FIG. 4 illustrates a Coomassie-Blue stained gel of purified recombinant proteins. One .mu.g of each of recombinant GroEL, recombinant GroES, recombinant BepA, recombinant RplL, and recombinant SodB were run on a 15% SDS-PAGE gel and stained with Coomassie Blue to demonstrate purity of these recombinant proteins. In the figure, the symbol "r" stands for the word "recombinant."

[0024] FIG. 5 illustrates serum IgG reactivity to recombinant GroEL, recombinant SodB, recombinant BepA, recombinant RplL, and recombinant GroES. These proteins were mixed in equal concentrations, and loaded into each lane of a 15% SDS-PAGE gel. After transfer, membranes were exposed to either patient sera (P) or normal sera (N). Bound antibodies were detected with anti-human IgG-horse-radish peroxidase ("HRP"). Blots shown are representative. In the figure, the symbol "r" stands for the word "recombinant."

[0025] FIG. 6 illustrates human serum IgG reactivity to recombinant GroEL, recombinant RplL, and recombinant 17 kDa antigen. Recombinant GroEL, recombinant RplL, and recombinant 17 kDa antigen were mixed in equal concentrations, and loaded into each lane of a 15% SDS-PAGE gel. After transfer, membranes were exposed to either patient sera (P) or normal sera (N). Bound antibodies were detected with anti-human IgG-HRP. Blots shown are representative. In the figure, the symbol "r" stands for the word "recombinant."

[0026] FIG. 7 illustrates a reactive epitope of RplL. Recombinant RplL was digested overnight with endoproteinase Arg-C. rRplL that had not undergone digestion (-) and rRplL that had (+) were loaded in equal amounts onto a 16.5% Tris-Tricine gel (A). After transfer, membranes were exposed to either patient sera (P) or normal sera (N). Bound antibodies were detected with anti-human IgG-HRP (B). Blots shown are representative.

DETAILED DESCRIPTION

[0027] The following examples illustrate the discovery that the GroES protein, the RplL protein, the BepA protein, the GroEL protein, the SodB protein, the UbiG protein, and the ABC transporter protein produced by Bartonella henselae are each antigenic. Each of these antigens can be used in an immunoassay to determine whether a subject possesses an antibody that binds to it. These examples are set forth by way of illustration only, and nothing therein shall be taken as a limitation upon the overall scope of the invention.

[0028] Techniques applicable to the present invention are described in Short Protocols in Molecular Biology, 5.sup.th edition, Volumes 1 and 2, 2002, Edited by Frederick M. Ausubel et al., John Wiley & Sons, Inc., Hoboken, N.J., the entire contents of which are hereby incorporated by reference; Short Protocols in Molecular Biology, 3.sup.rd edition, 1997, Edited by Frederick M. Ausubel et al., John Wiley & Sons, Inc., New York, N.Y., the entire contents of which are hereby incorporated by reference; Short Protocols in Immunology, 2005, Edited by John E. Coligan et al., John Wiley & Sons, Hoboken, N.J., the entire contents of which are hereby incorporated by reference; and The Immunoassay Handbook, 3.sup.rd Edition, 2005, Edited by David Wild, Elsevier, Amsterdam, San Diego, Calif., Oxford, the entire contents of which are hereby incorporated by reference.

EXAMPLE 1

Bartonella henselae Proteome

[0029] Bartonella henselae proteins were isolated from cultures of Bartonella henselae Houston-1. Bartonella henselae was grown to an optical density of 0.3 in 200 ml of BBH-H media at 37.degree. C., shaking at 180 rpm, for five days (Chenoweth, M. R., G. A. Somerville, D. C. Krause, K. L. O'Reilly, and F. C. Gherardini. 2004. Growth characteristics of Bartonella henselae in a novel liquid medium: primary isolation, growth-phase-dependent phage induction, and metabolic studies. Appl. Environ. Microbiol. 70:656-63.). The presence of Bartonella henselae in the culture was verified by an in-house PCR developed against the Bartonella henselae 16S rRNA. Culture pellets obtained by centrifugation were resuspended in PBS and sonicated. The soluble fraction was desalted using a desalting kit (BioRad, Hercules, Calif.) and resuspended in 8 M urea, 2% CHAPS, 40 mM DTT, 0.2% Bio-Lyte 3/10 ampholyte. The protein concentration was determined by a reducing agent-compatible detergent-compatible ("RC DC") assay (BioRad, Hercules, Calif.).

[0030] Three different protein fractions were obtained based on protein solubilities. Fraction 1 contained proteins with the highest solubility and 2-3 times the amount of protein isolated in fraction 2, which contained proteins of intermediate solubility. Fraction 3 contained proteins less soluble than those in fraction 2 and yielded 2-3 times less protein than that isolated in fraction 2.

[0031] Proteins from each fraction were separated by two-dimensional electrophoresis. 180 .mu.g of protein were loaded onto pH 3-10 immobilized pH gradient ("IPG") strips (BioRad, Hercules, Calif.) during overnight passive gel rehydration. Isoelectric Focusing ("IEF") was performed under standard conditions. Focused IEF strips were equilibrated for 15 minutes in 6 M urea, 2% SDS, 0.05 M Tris/HCI, 20% glycerol, 2% DTT and then 15 minutes in 6 M urea, 2% SDS, 0.05 M Tris/HCI, 20% glycerol, 2.5% iodoacetamide and then overlayed onto a 8-15% gradient SDS-PAGE gel (BioRad, Hercules, Calif.). The gels were run for 65 minutes at 200V.

[0032] Separations utilized a narrow pH range (5-8) and demonstrated a decrease in the number of proteins concomitant with a decrease in solubility. Computer analysis using PDQueSt.TM. (BioRad, Hercules, Calif.) identified over 900 protein spots in fraction 1,358 spots in fraction 2, and 138 spots in fraction 3 (FIGS. 1A-C). Fraction 1 required minimal processing and smaller amounts of Bartonella henselae culture to prepare and still yielded a significant number of spots. Hence, fraction 1 was pursued further in these studies. Use of IPG strips with a pH 3-10 resulted in an increase in the number of proteins observed in fraction 1 to more than 1000 spots (FIG. 1D).

[0033] Spots of interest were excised from Coomassie-Blue stained gels and sent for Matrix Assisted Laser Desorption Ionization Mass Spectrometry "MALDI-MS" peptide fingerprinting. This resulted in identification of proteins of interest. The genes encoding these proteins were subsequently amplified from Bartonella henselae DNA and ligated into a pET30 Ek/LIC expression vector (EMI Biosciences, San Diego, Calif.) (Table 1). Protein expression by transformed DH5.alpha. cells was induced using the Overnight Express.TM. AutoInduction System (EMD Biosciences, San Diego, Calif.). Proteins were purified by two passages over a nickel-nitrilotriacetic acid ("Ni-NTA") resin column (EMD Biosciences, San Diego, Calif.). After completion of buffer exchange into PBS, the proteins were concentrated. Final protein concentrations were determined by bicinchoninic acid ("BCA") assay. TABLE-US-00001 TABLE 1 Primers used for cloning of Bartonella henselae genetic material into the pET30EK/LIC vector. Protein Forward Primer Reverse Primer GroEL 5'-GACGACGACAAGATGGCTGCT- 5'-GAGGAGAAGCCCGGTTTAGAA- AAAGAAGTGAAGTTTGGC-3' GTCCATGCCGCCCA-3' (SEQ ID NO:1) (SEQ ID NO:2) GroES 5'-GACGACGACAAGATGGCTAAC- 5'-GAGGAGAAGCCCGGTTAACCC- ATACAAT-3' AAAATCCCCATAA-3' (SEQ ID NO:3) (SEQ ID NO:4) BepA 5'-GACGACGACAAGATGATAAGA- 5'-GAGGAGAAGCCCGGTTTAGCC- AAAACAGTTCCCAA-3' TTTTAGGGTTTT-3' (SEQ ID NO:5) (SEQ ID NO:6) RplL 5'-GACGACGACAAGATGGCTGAT- 5'-GAGGAGAAGCCCGGTTTATTT- CTAGCGAAGA-3' AAGTTCAACTTTAGCA-3' (SEQ ID NO:7) (SEQ ID NO:8) SodB 5'-GACGACGACAAGATGGCTTTT- 5'-GAGGAGAAGCCCGGTTTAAAG- GAACTAGCACCTT-3' TCCGCAATCTTCATA-3' (SEQ ID NO:9) (SEQ ID NO:10)

EXAMPLE 2

Reactivity of Patient Sera to Bartonella henselae Soluble Proteins

[0034] In order to determine which Bartonella henselae proteins can bind to antibodies, Western blots were performed using a two-dimensional map of fraction 1 using patient and normal human sera. Bartonella henselae IFA positive and negative human serum samples were purchased from Dr. D. Raoult (Universite de la Mediterranee, France) and from Focus Diagnostics (Cypress, Calif.). Serum samples with Bartonella henselae IFA titers.gtoreq.1:64 were considered positive sera, samples with IFA titers<1:64 were considered negative sera. All serum samples were verified in-house by IFA (Focus Diagnostics, Cypress, Calif.) prior to use.

[0035] Western blotting was performed using a standard protocol. Briefly, proteins were electrophoretically transferred from SDS-PAGE gels onto polyvinyldine difluoride ("PVDF") membranes. Transfer was performed at 100V for 60 minutes. After transfer, the membranes were stained with RedAlert.TM. (EMD Biosciences, San Diego, Calif.). The membranes were washed in PBS-Tween 20 and exposed to a 1:500 dilution of either normal or patient sera diluted in 1% bovine serum albumin (BSA)-PBS-Tween 20 for one hour. After washing of the membrane, anti-human IgG-HRP (KPL, Gaithersburg, Md.) was added at a dilution of 1:2000 in 1% BSA-PBS-Tween 20. 0.5 mg/ml 3,3'-diaminobenzidine (DAB; Sigma, St. Louis, Mo.) was then added. After exposure to substrate, the blots were imaged and analyzed by the software package PDQuest.TM..

[0036] Analysis of fourteen patient (Bartonella henselae IFA-positive) sera revealed reactivity to many Bartonella henselae proteins (FIG. 2A). In contrast, the seven normal (Bartonella henselae IFA-negative) sera tested demonstrated minimal reactivity to Bartonella henselae spots (FIG. 2B). Surprisingly, comparison of spot reactivities by PDQueSt.TM. between all patient sera tested demonstrated no common protein reactivity between all samples. However, at least seven spots demonstrated reactivity to greater than 64% of the patient sera tested (FIG. 3 and Table 2). These spots reacted to 0-14% of the normal sera tested (Table 2). TABLE-US-00002 TABLE 2 Reactivity of patient (Bartonella henselae IFA positive) and normal (Bartonella henselae IFA negative) sera to noted spots. Patient Sera Normal Sera Spot Designation (% reactivity) (% reactivity) A 10/14 (71%) 1/7 (14%) B 12/14 (86%) 1/7 (14%) E 9/14 (64%) 0/7 (0%) F 9/14 (64%) 0/7 (0%) G 9/14 (64%) 0/7 (0%) H 10/14 (71%) 1/7 (14%) J 9/14 (64%) 1/7 (14%)

EXAMPLE 3

Identification of Reactive Spots

[0037] Protein spots were excised from a Coomassie-Blue stained gel, and subjected to trypsin digestion and identification by MALDI-MS. Comparison of the molecular weights of the resultant trypsin fragments to the expected molecular weights of the digestion products from the Bartonella henselae genome sequence revealed the identities of these proteins (Table 3). Spot A was identified as GroES, a chaperonin. Spot B was identified as RplL, the L7/L12 segment of the 50S ribosome subunit. Spots E and F were identified as BepA, which has an unknown function. Spot G was identified as GroEL, a heat shock protein. Spot H was identified as SodB, a superoxide dismutase, and also was identified as UbiG, a chaperonin and a heat shock protein. Spot J was identified as the ABC transporter. TABLE-US-00003 TABLE 3 Properties of identified proteins. Spot Accession MW Gene Size Putative SEQ ID Designation Protein No. (kDa) pI (bp) Function NO: A GroES 49476035 10.7 5.23 297 chaperonin 11 B RplL 49475397 12.7 4.61 369 50S ribosomal 12 protein L7/L12 E, F BepA 49476039 19.7 6.15 525 unknown 13 G GroEL 6226790 57.6 4.91 1644 chaperonin, heat 14 shock protein H SodB 49475260 23.1 5.75 600 superoxide 15 dismutase H UbiG 49475201 28 7.35 741 3-dimethyl 16 ubiquinone-93- methyltransferase J ABC 49475425 28.2 5.41 750 periplasmic amino 17 transporter acid-binding protein

[0038] The amino acid sequence of each of the GroES, RplL, BepA, GroEL, SodB, UbiG, and the ABC transporter proteins was previously published (see Table 3 for the respective accession numbers). The gene encoding each of the GroEL, GroES, BepA, RplL, and SodB proteins was cloned and expressed with an N-terminal histidine tag that allowed for purification over an Ni.sup.2+ column. After purification, protein fractions were run on an SDS-PAGE gel which revealed an estimated purity of greater than 90% for each protein isolated (FIG. 4).

EXAMPLE 4

Western Analysis of Patient Sera to Select Bartonella henselae Proteins

[0039] Western analysis of two-dimensional gels revealed the overall reactivity of patient sera to Bartonella henselae suggesting five proteins for further study (GroES, GroEL, SodB, RplL, and BepA). In order to determine the reactivity of sera to these proteins, recombinant GroES, recombinant GroEL, recombinant SodB, recombinant RplL, and recombinant BepA were simultaneously separated by one-dimensional SDS-PAGE gels and subsequently electrophoretically transferred to PVDF membranes. Individual lanes containing all of the chosen proteins were screened with either patient or normal sera (FIG. 5). Patient sera demonstrated reactivity to all proteins in various combinations. However, normal serum demonstrated recognition of recombinant SodB and recombinant BepA. Recombinant SodB and recombinant BepA were not analyzed further due to this reactivity.

[0040] A subsequent Western blot was produced that combined recombinant GroEL, recombinant RplL, and the recombinant 17 kDa protein. The 17 kDa protein has been previously used in an ELISA to determine if patients have an antibody response to Bartonella henselae; although normal sera did not demonstrate greater than background reactivity to the 17 kDa protein, not all patient sera contain antibodies to this protein (Loa, C. C., E. Mordechai, R. C. Tilton, and M. E. 2006. Adelson. Production of recombinant Bartonella henselae 17 kDa protein for antibody-capture ELISA. Diagnostic Microbiology and Infectious Disease. In Press). Utilization of recombinant GroEL, recombinant RplL and recombinant 17 kDa protein in combination resulted in recognition of at least one band by twenty-four of twenty-eight patient sera and seven of twenty-one normal sera (FIG. 6). Thus, this Western blot has a sensitivity of 85.7% and a specificity of 66.7%.

EXAMPLE 5

Proteolytic and Chemical Digestion of RplL

[0041] In an effort to localize the immunodominant and cross-reactive regions of RplL and impart increased specificity to the Western blot assay, digestions of recombinant RplL were performed. Recombinant RplL (18 .mu.g) was digested with 29 .mu.g 3-bromo-2-(2-nitrophenylsulfenyl)skatol ("BNPS-skatol") (MP Biomedicals, Irvine, Calif.) in 100% acetic acid overnight at 47.degree. C. The reaction was stopped by the addition of 24 .mu.l of ddH.sub.2O. Recombinant RplL (55 .mu.g) was incubated with 1 .mu.g endoproteinase Arg-C (Calbiochem, San Diego, Calif.), activation solution (5 mM DTT, 0.5 mM EDTA) and incubation solution (0.1 M Tris HCl, 0.01 M CaCl.sub.2). The reaction was incubated overnight at 37.degree. C.

[0042] Based on sequence analysis, chemical digestion with BNPS-skatol cleaves recombinant RplL at one site (after the amino acid residue at position 73) resulting in fragments of approximately 8200 and 9400 Da in size. Proteolytic digestion with endoproteinase Arg-C results in cleavage at three sites (after the amino acid residues at positions 14, 28, and 119) resulting in fragments of approximately 1700, 1500, 9500, and 4900 Da in size. Recombinant RplL was digested using these two methods, which resulted in fragments of the appropriate size (data not shown). Subsequent Western analysis was performed utilizing patient and normal human sera (FIG. 7). Cleavage with BNPS-skatol did not provide any additional evidence for the localization of epitopes. However, patient sera appeared to bind most frequently to an approximately 10 kDa fragment that resulted from endoproteinase Arg-C digestion of rRplL (see SEQ ID NO:18 for the amino acid sequence of this 10 kDa fragment). Ten of eleven patient sera bound to a 10 kDa digestion product, while three of twelve normal sera bound.

EXAMPLE 6

ELISA Analysis

[0043] In order to provide a semi-quantitative result, ELISAs using recombinant proteins as the solid phase were developed. Purified proteins diluted in coating buffer (0.015 M Na.sub.2CO.sub.3, 0.035 M NaHCO.sub.3 (pH 9.6)) were used to coat 96-well Immulon 2 high-binding plates (DYNEX Technologies, Chantilly, Va.). Recombinant GroES, recombinant GroEL, recombinant RplL, and recombinant BepA were used at 0.25, 0.25, 0.01, and 2 .mu.g/ml, respectively, to coat plates. After overnight incubation at 4.degree. C., the plates were washed with PBS-Tween 20, blocked with 1% BSA for one hour at 37.degree. C., and washed again. Dilutions of serum in 1% bovine serum albumin were added and then incubated for one hour at 37.degree. C. Antigen-specific antibodies were detected by goat anti-human IgG-HRP (KPL, Gaithersburg, Md.) and developed with 3,3',5,5'-tetramethylbenzidine ("TMB") (Moss, Pasadena, Md.) for fifteen minutes. The reaction was stopped with 1N HCl and the absorbance at 450 nm was recorded after a standardized period of ten minutes.

[0044] An ELISA using recombinant RplL as the coating antigen demonstrated reactivity to fourteen of eighteen patient sera and seven of seventeen normal sera. This ELISA exhibited a sensitivity of 78% and a specificity of 59% (Table 4). Sixteen of twenty patient sera and fourteen of twenty normal sera demonstrated reactivity by recombinant GroEL ELISA. Recombinant GroES ELISA demonstrated reactivity with sixteen of twenty patient sera and seventeen of twenty normal sera. An ELISA using recombinant BepA as the coating antigen demonstrated reactivity to twelve of fourteen patient sera and five of nine normal sera. Sensitivities and specificities of ELISAs based on these proteins was determined (Table 4). TABLE-US-00004 TABLE 4 Sensitivities and specificities of ELISAs using various recombinant proteins as coating antigens. Recombinant Protein Sensitivity (%) Specificity (%) recombinant GroES 80 15 recombinant RplL 78 59 recombinant BepA 86 44 recombinant GroEL 80 30

[0045]

Sequence CWU 1

1

18 1 39 DNA Bartonella henselae 1 gacgacgaca agatggctgc taaagaagtg aagtttggc 39 2 35 DNA Bartonella henselae 2 gaggagaagc ccggtttaga agtccatgcc gccca 35 3 28 DNA Bartonella henselae 3 gacgacgaca agatggctaa catacaat 28 4 34 DNA Bartonella henselae 4 gaggagaagc ccggttaacc caaaatcccc ataa 34 5 35 DNA Bartonella henselae 5 gacgacgaca agatgataag aaaaacagtt cccaa 35 6 33 DNA Bartonella henselae 6 gaggagaagc ccggtttagc cttttagggt ttt 33 7 31 DNA Bartonella henselae 7 gacgacgaca agatggctga tctagcgaag a 31 8 37 DNA Bartonella henselae 8 gaggagaagc ccggtttatt taagttcaac tttagca 37 9 34 DNA Bartonella henselae 9 gacgacgaca agatggcttt tgaactagca cctt 34 10 36 DNA Bartonella henselae 10 gaggagaagc ccggtttaaa gtccgcaatc ttcata 36 11 98 PRT Bartonella henselae 11 Met Ala Asn Ile Gln Phe Arg Pro Leu His Asp Arg Val Val Val Arg 1 5 10 15 Arg Val Glu Ser Glu Asn Lys Thr Ala Gly Gly Ile Ile Ile Pro Asp 20 25 30 Thr Ala Lys Glu Lys Pro Gln Glu Gly Glu Val Ile Ala Val Gly Asn 35 40 45 Gly Ala Leu Asp Asp Asn Gly Lys Arg Val Pro Leu Glu Val Lys Thr 50 55 60 Gly Asp Arg Ile Leu Phe Gly Lys Trp Ser Gly Thr Glu Val Lys Ile 65 70 75 80 Asn Gly Glu Asp Leu Leu Ile Met Lys Glu Ser Asp Ile Met Gly Ile 85 90 95 Leu Gly 12 123 PRT Bartonella henselae 12 Met Ala Asp Leu Ala Lys Ile Val Glu Asp Leu Ser Asn Leu Thr Val 1 5 10 15 Leu Glu Ala Ala Glu Leu Ser Lys Leu Leu Glu Glu Lys Trp Gly Val 20 25 30 Ser Ala Ala Ala Pro Val Ala Val Ala Ala Val Ala Gly Ala Ala Ala 35 40 45 Pro Val Ala Glu Glu Lys Thr Glu Phe Asp Val Ile Leu Val Glu Gly 50 55 60 Gly Ala Gln Lys Ile Asn Val Ile Lys Glu Val Arg Ala Leu Thr Gly 65 70 75 80 Leu Gly Leu Lys Glu Ala Lys Asp Leu Val Glu Gly Ala Pro Lys Pro 85 90 95 Ile Lys Glu Gly Ala Ser Lys Asp Glu Ala Glu Lys Ile Lys Ser Gln 100 105 110 Leu Glu Ala Ala Gly Ala Lys Val Glu Leu Lys 115 120 13 174 PRT Bartonella henselae 13 Met Ile Arg Lys Thr Val Pro Asn Thr Thr Phe His Thr Arg Val Arg 1 5 10 15 Asp Glu Ser Ile Gly Gly Asp Asn Pro Tyr Arg Trp Gln Glu Val Asn 20 25 30 Ser Asp Ala Tyr Phe Lys Gly Lys Arg Val Ile Leu Phe Ser Leu Pro 35 40 45 Gly Ala Phe Thr Pro Thr Cys Ser Thr Phe Gln Leu Pro Asp Phe Glu 50 55 60 Lys Leu Tyr Asp Glu Phe Lys Lys Val Gly Ile Asp Glu Ile Tyr Cys 65 70 75 80 Leu Ser Val Asn Asp Ala Phe Val Met Asn Ala Trp Gly Lys Ala Gln 85 90 95 Gly Ile Lys Asn Val Lys Leu Ile Pro Asp Gly Ser Gly Glu Phe Thr 100 105 110 Arg Lys Met Gly Met Leu Val Ala Lys Asp Asn Val Gly Phe Gly Met 115 120 125 Arg Ser Trp Arg Tyr Ala Ala Val Ile Asn Asp Gly Val Ile Glu His 130 135 140 Trp Phe Glu Glu Gln Gly Phe Ser Asp Asn Cys Ala Thr Asp Pro Tyr 145 150 155 160 Glu Val Ser Ser Pro Gln Asn Val Leu Lys Thr Leu Lys Gly 165 170 14 547 PRT Bartonella henselae 14 Met Ala Ala Lys Glu Val Lys Phe Gly Arg Glu Ala Arg Glu Arg Leu 1 5 10 15 Leu Arg Gly Val Asp Ile Leu Ala Asn Ala Val Lys Val Thr Leu Gly 20 25 30 Pro Lys Gly Arg Asn Val Val Ile Asp Lys Ser Phe Gly Ala Pro Arg 35 40 45 Ile Thr Lys Asp Gly Val Ser Val Ala Lys Glu Ile Glu Leu Glu Asp 50 55 60 Lys Phe Glu Asn Met Gly Ala Gln Met Leu Arg Glu Val Ala Ser Lys 65 70 75 80 Thr Asn Asp Ile Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Gly 85 90 95 Gln Ala Ile Val Gln Glu Gly Val Lys Ala Val Ala Ala Gly Met Asn 100 105 110 Pro Met Asp Leu Lys Arg Gly Ile Asp Ala Ala Val Asp Glu Val Val 115 120 125 Ala Asn Leu Phe Lys Lys Ala Lys Lys Ile Gln Thr Ser Ala Glu Ile 130 135 140 Ala Gln Val Gly Thr Ile Ser Ala Asn Gly Ala Ala Glu Ile Gly Lys 145 150 155 160 Met Ile Ala Asp Ala Met Glu Lys Val Gly Asn Glu Gly Val Ile Thr 165 170 175 Val Glu Glu Ala Lys Thr Ala Glu Thr Glu Leu Glu Val Val Glu Gly 180 185 190 Met Gln Phe Asp Arg Gly Tyr Leu Ser Pro Tyr Phe Val Thr Asn Ala 195 200 205 Glu Lys Met Val Ala Asp Leu Asp Asp Pro Tyr Ile Leu Ile His Glu 210 215 220 Lys Lys Leu Ser Asn Leu Gln Ser Leu Leu Pro Val Leu Glu Ala Val 225 230 235 240 Val Gln Ser Gly Lys Pro Leu Leu Ile Ile Ala Glu Asp Val Glu Gly 245 250 255 Glu Ala Leu Ala Thr Leu Val Val Asn Lys Leu Arg Gly Gly Leu Lys 260 265 270 Ile Ala Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met 275 280 285 Leu Glu Asp Ile Ala Ile Leu Thr Ser Gly Gln Val Ile Ser Glu Asp 290 295 300 Val Gly Ile Lys Leu Glu Asn Val Thr Leu Asp Met Leu Gly Arg Ala 305 310 315 320 Lys Lys Val Asn Ile Ser Lys Glu Asn Thr Thr Ile Ile Asp Gly Ala 325 330 335 Gly Gln Lys Ser Glu Ile Asn Ala Arg Val Asn Gln Ile Lys Val Gln 340 345 350 Ile Glu Glu Thr Thr Ser Asp Tyr Asp Arg Glu Lys Leu Gln Glu Arg 355 360 365 Leu Ala Lys Leu Ala Gly Gly Val Ala Val Ile Arg Val Gly Gly Ala 370 375 380 Thr Glu Val Glu Val Lys Glu Lys Lys Asp Arg Val Asp Asp Ala Leu 385 390 395 400 Asn Ala Thr Arg Ala Ala Val Glu Glu Gly Ile Val Ala Gly Gly Gly 405 410 415 Thr Ala Leu Leu Arg Ala Ala Asn Ala Leu Thr Val Lys Gly Ser Asn 420 425 430 Pro Asp Gln Glu Ala Gly Ile Asn Ile Val Arg Arg Ala Leu Gln Ala 435 440 445 Pro Ala Arg Gln Ile Ala Thr Asn Ala Gly Glu Glu Ala Ala Ile Ile 450 455 460 Val Gly Lys Val Leu Glu Asn Asn Ala Asp Thr Phe Gly Tyr Asn Thr 465 470 475 480 Ala Thr Gly Glu Phe Gly Asp Leu Ile Ala Leu Gly Ile Val Asp Pro 485 490 495 Val Lys Val Val Arg Ser Ala Leu Gln Asn Ala Ala Ser Ile Ala Ser 500 505 510 Leu Leu Ile Thr Thr Glu Ala Met Val Ala Glu Val Pro Lys Lys Asp 515 520 525 Thr Pro Val Pro Pro Met Pro Gly Gly Gly Met Gly Gly Met Gly Gly 530 535 540 Met Asp Phe 545 15 200 PRT Bartonella henselae 15 Met Ala Phe Glu Leu Ala Pro Leu Pro Tyr Asp Tyr Asp Ser Leu Ser 1 5 10 15 Pro Tyr Met Ser Arg Glu Thr Leu Glu Tyr His His Asp Lys His His 20 25 30 Leu Ala Tyr Leu Thr Asn Thr Asn Asn Phe Val Lys Asp Leu Gly Leu 35 40 45 Glu Asn Glu Ser Leu Glu Asn Ile Val Lys Lys Ser Phe Gly Gln Asn 50 55 60 Ile Gly Leu Phe Asn Asn Ala Ala Gln Tyr Tyr Asn His Asn His Phe 65 70 75 80 Trp His Trp Met Lys Lys Gly Gly Gly Gly Gln Lys Leu Pro Glu Lys 85 90 95 Leu Ala Lys Ala Ile Glu Ser Asp Leu Gly Gly Tyr Asp Lys Phe Arg 100 105 110 Ala Asp Phe Ile Ala Thr Ala Ile Ala Gln Phe Gly Ser Gly Trp Ala 115 120 125 Trp Ile Ala Val Lys Asp Gly Lys Leu Glu Ile Met Lys Thr Pro Asn 130 135 140 Gly Glu Asn Pro Leu Val His Asn Ala Gln Pro Ile Leu Gly Val Asp 145 150 155 160 Val Trp Glu His Ser Tyr Tyr Ile Asp Tyr Arg Asn Val Arg Pro Lys 165 170 175 Tyr Leu Glu Ala Phe Val Asp His Leu Ile Asn Trp Asp Tyr Val Leu 180 185 190 Lys Leu Tyr Glu Asp Cys Gly Leu 195 200 16 247 PRT Bartonella henselae 16 Met Ile Asn Glu Thr Arg Thr Thr Leu Asp Gln Ser Glu Val Asp His 1 5 10 15 Phe Ser Arg Ile Ala Ala Glu Trp Trp Asn Pro His Gly Lys Phe Arg 20 25 30 Pro Leu His Gln Phe Asn Pro Thr Arg Leu Ala Tyr Ile Arg Glu Lys 35 40 45 Ile Cys Leu Glu Leu His Arg Asp Pro Val Ser Leu Lys Pro Phe Glu 50 55 60 Asn Leu Lys Ile Leu Asp Ile Gly Cys Gly Gly Gly Leu Leu Cys Glu 65 70 75 80 Pro Met Ala Arg Leu Gly Ala Met Val Val Gly Ala Asp Ala Ser Gln 85 90 95 Thr Asn Ile Glu Val Ala Lys Ile His Ala Ala Gln Asn Gly Leu Ser 100 105 110 Ile Asp Tyr Arg Thr Thr Thr Ala Glu Ala Leu Ala Thr Glu Gly Glu 115 120 125 Gln Phe Asp Ile Ile Leu Asn Met Glu Val Val Glu His Val Ala Asp 130 135 140 Val Asn Leu Phe Ile Glu Ala Thr Ala Lys Met Leu Lys Pro Gln Gly 145 150 155 160 Leu Met Phe Ile Ser Thr Leu Asn Arg Thr Trp Lys Ala Trp Gly Leu 165 170 175 Ala Ile Ile Gly Ala Glu Tyr Ile Leu Arg Trp Leu Pro Lys Gly Thr 180 185 190 His Asn Tyr Lys Lys Phe Leu Lys Pro Arg Glu Leu Lys Asn Leu Leu 195 200 205 Leu Gln Asn Ala Leu Thr Val Val Asp Glu Ile Gly Val Thr Tyr Asn 210 215 220 Pro Leu Asn Asp Ser Trp Asn Arg Ser Lys Asp Met Asn Val Asn Tyr 225 230 235 240 Leu Leu Leu Ala Lys Lys Ser 245 17 250 PRT Bartonella henselae 17 Met Lys Leu Leu Ala Val Ala Leu Ile Thr Asn Leu Val Leu Phe Thr 1 5 10 15 Gln Leu Ala Asn Ala Lys Thr Leu Lys Ile Ala Ser Asp Ala Ser Tyr 20 25 30 Pro Pro Phe Ser Tyr Val Asn Ser Asn Asn Glu Leu Gln Gly Phe Asp 35 40 45 Ile Asp Ile Ser Tyr Ala Leu Cys Lys Lys Met Asn Val Glu Cys Thr 50 55 60 Ile Val Thr Gln Asp Phe Glu Gly Met Ile Pro Gly Leu Leu Ala Lys 65 70 75 80 Lys Tyr Asp Ala Ile Ile Ser Ser Leu Ala Pro Thr Glu Glu Arg Leu 85 90 95 Gln Lys Ile Asp Phe Thr Asp Ala Tyr Tyr Ser Thr Glu Leu Val Val 100 105 110 Ile Val His Lys Asp Ser Gly Ile Lys Glu Ile Ser Ala Glu Ala Phe 115 120 125 Lys Asp Lys Asn Leu Gly Val Gln Ser Asn Thr Thr Gln Ala Val Tyr 130 135 140 Ala Glu Asp His Tyr Ala Ala Glu Gly Val Asn Ile Lys Leu Tyr Pro 145 150 155 160 Thr Ala Ile Glu Val Lys Arg Asp Leu Leu Ser His Arg Leu Asp Ile 165 170 175 Val Ile Ser Asp Lys Leu Ala Ala Val Asn Trp Leu Glu Asn Glu Glu 180 185 190 Lys Asp Cys Cys Gln Leu Leu Gly Ser Leu Lys Lys Thr Lys Leu Pro 195 200 205 Ile Ala Ile Ala Ile Arg Lys Asn Asn Asn Asp Leu Lys Asn Lys Phe 210 215 220 Asn Glu Ala Ile Lys Glu Ile Arg Glu Asp Gly Thr Tyr Asp Lys Ile 225 230 235 240 Met Lys Lys Tyr Phe Thr Phe Asp Ile Tyr 245 250 18 91 PRT Bartonella henselae 18 Lys Trp Gly Val Ser Ala Ala Ala Pro Val Ala Val Ala Ala Val Ala 1 5 10 15 Gly Ala Ala Ala Pro Val Ala Glu Glu Lys Thr Glu Phe Asp Val Ile 20 25 30 Leu Val Glu Gly Gly Ala Gln Lys Ile Asn Val Ile Lys Glu Val Arg 35 40 45 Ala Leu Thr Gly Leu Gly Leu Lys Glu Ala Lys Asp Leu Val Glu Gly 50 55 60 Ala Pro Lys Pro Ile Lys Glu Gly Ala Ser Lys Asp Glu Ala Glu Lys 65 70 75 80 Ile Lys Ser Gln Leu Glu Ala Ala Gly Ala Lys 85 90

Claims

1. An isolated antibody capable of binding to an antigen, wherein the antigen consists of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.

2. The antibody of claim 1 being human.

3. The antibody of claim 1 being polyclonal.

4. A kit containing (a) an isolated antigen comprising the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO 18 and (b) the reagents necessary for conducting an immunoassay, wherein the immunoassay is capable of detecting the presence of an antibody in a sample, and wherein the antibody is capable of binding to an antigen consisting of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.

5. The kit of claim 4, wherein the immunoassay is an IFA.

6. The kit of claim 4, wherein the immunoassay is an ELISA.

7. The kit of claim 4, wherein the isolated antigen in (a) consists of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.

8. A method for determining whether a subject contains an antibody capable of binding to an antigen consisting of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18 comprising: (a) conducting an immunoassay on a sample from the subject, and (b) determining that the subject contains the antibody if the results of the immunoassay indicate that the antibody is present in the sample, or determining that the subject does not contain the antibody if the results of the immunoassay indicate that the antibody is not present in the sample.

9. The method of claim. 8, wherein the subject is human.

10. The method of claim 8, wherein the immunoassay is an IFA.

11. The method of claim 8, wherein the immunoassay is an ELISA.

12. A method for determining whether a subject has an increased likelihood of being infected presently or in the past with Bartonella henselae comprising: (a) conducting an immunoassay on a sample from the subject, and (b) determining that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae if the results of the immunoassay indicate that an antibody is present in the sample, or determining that the subject does not have an increased likelihood of being infected presently or in the past with Bartonella henselae if the results of the immunoassay indicate that the antibody is not present in the sample, wherein the antibody is capable of binding to an antigen consisting of the amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.

13. The method of claim 12, wherein the subject is human.

14. The method of claim 12, wherein the immunoassay is an IFA.

15. The method of claim 12, wherein the immunoassay is an ELISA.

16. A method for determining whether a subject has a present infection with Bartonella henselae or had a past infection with Bartonella henselae comprising: (a) conducting an immunoassay on a sample from the subject, and (b) determining that the subject has a present infection with Bartonella henselae or had a past infection with Bartonella henselae if the results of the immunoassay indicate that an antibody is present in the sample, or determining that the subject does not have a present infection with Bartonella henselae or did not have a past infection with Bartonella henselae if die results of the immunoassay indicate that the antibody is not present in the sample, wherein the antibody is capable of binding to an antigen consisting of tile amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.

17. The method of claim 16, wherein the subject is human.

18. The method of claim 16, wherein the immunoassay is an IFA.

19. The method of claim 16, wherein the immunoassay is an ELISA.

20. The kit of claim 4, wherein the immunoassay comprises Western blotting.

21. The method of claim 8, wherein the immunoassay comprises Western blotting.

22. The method of claim 12, wherein the immunoassay comprises Western blotting.

23. The method of claim 16, wherein the immunoassay comprises Western blotting.